Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19194571 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19194480 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19187484 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | April 2025 | November 2025 | Allow | 7 | 1 | 0 | No | No |
| 19092801 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | March 2025 | October 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19028692 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | January 2025 | August 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18933567 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933750 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933499 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18933645 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | October 2024 | April 2025 | Allow | 5 | 2 | 0 | Yes | No |
| 18891208 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | October 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18891221 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | October 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18891189 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18889137 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18807591 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | August 2024 | November 2024 | Allow | 3 | 0 | 1 | No | No |
| 18665736 | MGAT1 DEFICIENT CELLS AND USES THEREOF | May 2024 | October 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18586689 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 0 | No | No |
| 18393408 | miRNA Switches for RNA-Triggered Control of RNA Interference | December 2023 | March 2025 | Allow | 15 | 3 | 0 | Yes | No |
| 18518177 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | November 2023 | February 2025 | Allow | 15 | 3 | 1 | Yes | No |
| 18504827 | MICROORGANISMS AND USES THEREOF | November 2023 | January 2025 | Abandon | 14 | 1 | 1 | No | No |
| 18288340 | MICROORGANISMS AND USES THEREOF | October 2023 | February 2026 | Abandon | 28 | 1 | 1 | No | No |
| 18362675 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | July 2023 | May 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18343014 | RNA AND DNA ANALYSIS USING ENGINEERED SURFACES | June 2023 | December 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18269089 | INCREASED PACKAGING EFFICIENCY OF VECTOR FOR CARDIAC GENE THERAPY | June 2023 | February 2026 | Allow | 31 | 0 | 0 | No | No |
| 18144276 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 1 | No | No |
| 18040302 | COMPOSITIONS AND METHODS FOR INHIBITING LPA EXPRESSION | February 2023 | June 2025 | Allow | 28 | 1 | 1 | No | No |
| 17882099 | Compositions and Methods for Kallikrein (KLKB1) Gene Editing | August 2022 | October 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17792507 | RAB13 AND NET1 ANTISENSE OLIGONUCLEOTIDES TO TREAT METASTATIC CANCER | July 2022 | August 2025 | Allow | 37 | 0 | 1 | Yes | No |
| 17830842 | COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION | June 2022 | February 2026 | Allow | 44 | 1 | 0 | No | No |
| 17679977 | CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTOR | February 2022 | November 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17675229 | METAL ION-START DNA POLYMERASE SWITCH AND ISOTHERMAL POLYMERASE AMPLIFICATION METHOD USING THE SAME | February 2022 | August 2024 | Allow | 30 | 2 | 0 | Yes | No |
| 17635894 | USE OF MÜLLERIAN INHIBITING SUBSTANCE INHIBITORS FOR TREATING CANCER | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17583594 | Reporting Construct with Synaptobrevin Based Moiety | January 2022 | December 2024 | Allow | 35 | 2 | 0 | No | No |
| 17582594 | SOLUTE CARRIER FAMILY 46 MEMBER 3 (SLC46A3) AS MARKER FOR LIPID-BASED NANOPARTICLE CANCER THERAPY AND DIAGNOSTICS | January 2022 | October 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17610588 | APTAMER SPECIFICALLY BINDING TO KRAS PROTEIN AND METHOD FOR USING SAME | November 2021 | December 2025 | Abandon | 50 | 1 | 0 | No | No |
| 17607552 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | October 2021 | December 2025 | Abandon | 49 | 0 | 1 | No | No |
| 17606486 | PROBES FOR DETECTING RNA AND METHODS OF USE THEREOF | October 2021 | February 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17606292 | PROBIOTIC STRAINS HAVING INCREASED STORAGE STABILITY | October 2021 | September 2025 | Allow | 47 | 1 | 1 | No | No |
| 17604880 | p16INK4a INHIBITOR FOR PREVENTING OR TREATING HUNTINGTON'S DISEASE | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17593951 | APTAMER SPECIFICALLY BINDING TO CANCER STEM CELLS, AND USE THEREOF | September 2021 | February 2026 | Allow | 53 | 2 | 1 | No | No |
| 17593826 | RNAI MOLECULE | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17441905 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | September 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17441620 | METHODS FOR TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17440139 | RSK INHIBITORS IN THE TREATMENT OF VIRUS DISEASES | September 2021 | April 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17436773 | RNA Aptamers and Uses Thereof | September 2021 | February 2026 | Allow | 53 | 2 | 0 | No | No |
| 17435205 | NEUROPROTECTIVE GENE THERAPY TARGETING THE AKT PATHWAY | August 2021 | September 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17432318 | PREVENTION OR TREATMENT OF FIBROTIC DISEASE | August 2021 | November 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17427814 | ONE-STEP GENE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY VIA GENE REPLACEMENT AND ANTI-INFLAMMATION | August 2021 | December 2025 | Allow | 52 | 2 | 0 | No | No |
| 17421277 | A METHOD OF TREATING CYSTIC FIBROSIS | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17420808 | TREATMENT OF FATTY LIVER DISEASE | July 2021 | February 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17415998 | APTAMER AGAINST IRINOTECAN | June 2021 | July 2025 | Allow | 49 | 2 | 1 | No | No |
| 17312740 | CONTROL OF INSECT INFESTATION | June 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17312721 | RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF | June 2021 | March 2026 | Allow | 57 | 3 | 1 | No | No |
| 17311949 | DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES CONTAINING A TRILOOP | June 2021 | September 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17311175 | ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9 | June 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17299355 | Cyclic Di-Nucleotide Compounds as STING Agonists | June 2021 | March 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17296163 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | May 2021 | November 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17294171 | Composition for Inhibiting Replication of Hepatitis B Virus | May 2021 | July 2025 | Allow | 50 | 3 | 0 | No | No |
| 17290582 | NEW THERAPY | April 2021 | October 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17245443 | ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1 | April 2021 | September 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17289311 | GENETICALLY-ENGINEERED MESENCHYMAL STEM CELLS OVEREXPRESSING AOAH AND USES THEREOF | April 2021 | September 2025 | Abandon | 53 | 2 | 0 | No | No |
| 17241227 | PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | April 2021 | July 2025 | Allow | 51 | 2 | 0 | Yes | No |
| 17231556 | Compositions and Methods for Immunotherapy | April 2021 | January 2026 | Allow | 57 | 3 | 1 | No | No |
| 17283322 | REGULATED GENE EDITING SYSTEM | April 2021 | August 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17282340 | OLIGONUCLEOTIDE MEDIATED NO-GO DECAY | April 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17212901 | Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing | March 2021 | July 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17204008 | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17275132 | L-OLIGONUCLEOTIDE INHIBITORS OF POLYCOMB REPRESSIVE COMPLEX 2 (PRC2) | March 2021 | June 2025 | Abandon | 51 | 1 | 1 | No | No |
| 17196531 | RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTD | March 2021 | October 2024 | Abandon | 44 | 1 | 1 | No | No |
| 17271549 | SYSTEMS AND METHODS RELATED TO OLIGONUCLEOTIDE BUFFERS | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17269488 | FACTOR IX ENCODING NUCLEOTIDES | February 2021 | September 2024 | Allow | 43 | 2 | 0 | No | No |
| 17269186 | TRANSLATION ENHANCER, TEMPLATE NUCLEIC ACID, PRODUCTION METHOD OF TRANSLATION TEMPLATE, AND PRODUCTION METHOD OF PROTEIN | February 2021 | July 2025 | Allow | 53 | 3 | 1 | Yes | No |
| 16973908 | COMPLEX FOR THE DELIVERY OF CAS9 PROTEINS AND GUIDE RNA TO CELLS | December 2020 | June 2025 | Abandon | 54 | 0 | 1 | No | No |
| 17052508 | REVERSE TRANSCRIPTASE SEQUENCE OF MARINE BACTERIOPHAGE AND USE THEREOF | November 2020 | June 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17052170 | IN UTERO CRISPR-MEDIATED THERAPEUTIC EDITING OF GENES | October 2020 | January 2026 | Allow | 60 | 2 | 1 | No | No |
| 16982977 | Immortalization of Splenic and Peripheral Blood Macrophages Using a Multi-Cistronic V-RAF/V-MYC Lentivirus | September 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 16960227 | SMARTBAC BACULOVIRUS EXPRESSION SYSTEM AND APPLICATION THEREOF | July 2020 | February 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16919423 | B4GALT1 Variants And Uses Thereof | July 2020 | July 2025 | Allow | 60 | 2 | 0 | Yes | No |
| 16901514 | BACTERIAL QUANTITATIVE TRAIT-LOCUS MAPPING | June 2020 | March 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 16760868 | CHEMICALLY-MODIFIED GUIDE RNAS TO IMPROVE CRISPR-CAS PROTEIN SPECIFICITY | April 2020 | May 2025 | Abandon | 60 | 3 | 1 | No | No |
| 16781891 | ALGORITHMS FOR DISEASE DIAGNOSTICS | February 2020 | May 2025 | Abandon | 60 | 1 | 1 | No | No |
| 16748267 | Method for Fragmenting Genomic DNA Using CAS9 | January 2020 | January 2025 | Abandon | 60 | 2 | 0 | No | No |
| 16560685 | Increasing Cellular Lipid Production by Increasing the Activity of Diacylglycerol Acyltransferase and Decreasing the Activity of Triacylglycerol Lipase | September 2019 | April 2025 | Abandon | 60 | 2 | 0 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner ZAHORIK, AMANDA MARY works in Art Unit 1636 and has examined 49 patent applications in our dataset. With an allowance rate of 34.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 51 months.
Examiner ZAHORIK, AMANDA MARY's allowance rate of 34.7% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZAHORIK, AMANDA MARY receive 1.33 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by ZAHORIK, AMANDA MARY is 51 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +76.2% benefit to allowance rate for applications examined by ZAHORIK, AMANDA MARY. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 38.9% of applications are subsequently allowed. This success rate is in the 89% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 45.5% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 20% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 23.5% of allowed cases (in the 94% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.